Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v2.4.0.8
Condensed Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Operating expenses:        
Research and development $ 452,600 $ 28,971 $ 683,960 $ 225,922
General and administrative 365,603 16,374 704,185 55,097
Total operating expenses 818,203 45,345 1,388,145 281,019
Operating loss (818,203) (45,345) (1,388,145) (281,019)
Other income (expense):        
Interest expense (650) (9,367) (23,045) (31,292)
Forgiveness of interest on note payable 7,466   7,466  
Interest income 802 128 1,425 695
Gain on the settlement of debt 145,006   145,006  
Change in fair value of warrant liability     (28,448) (21,910)
Foreign currency exchange (loss) gain 5,958 (4,968) 5,533 (856)
Other income (expense,) net 158,582 (14,207) 107,937 (31,453)
Net loss and comprehensive loss $ (659,621) $ (59,552) $ (1,280,208) $ (312,472)
Net loss and comprehensive loss per share, basic and diluted $ (0.03) $ (0.01) $ (0.07) $ (0.04)
Weighted average number of common shares outstanding, basic and diluted 25,542,755 6,964,788 18,242,956 6,964,788